Bamco Inc. NY Acquires New Holdings in Illumina, Inc. $ILMN

Bamco Inc. NY acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 227,094 shares of the life sciences company's stock, valued at approximately $39,930,000. Bamco Inc. NY owned 0.15% of Illumina as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Empowered Funds LLC boosted its holdings in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new stake in Illumina in the second quarter valued at approximately $621,000. CW Advisors LLC acquired a new stake in Illumina during the 2nd quarter worth $275,000. Marshall Wace LLP lifted its position in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after acquiring an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC increased its holdings in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock valued at $706,000 after purchasing an additional 1,748 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Trading Down 0.1%

NASDAQ ILMN opened at $224.84 on Thursday. The company has a 50-day simple moving average of $191.66 and a 200-day simple moving average of $154.42. The firm has a market capitalization of $33.95 billion, a PE ratio of 41.95, a price-to-earnings-growth ratio of 3.17 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a one year low of $88.00 and a one year high of $227.70.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a "hold" rating in a research report on Wednesday, August 5th. Evercore reissued an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Sanford C. Bernstein reiterated a "market perform" rating and set a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Zacks Research upgraded shares of Illumina from a "hold" rating to a "strong-buy" rating in a report on Monday, August 3rd. Finally, Weiss Ratings upgraded Illumina from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Illumina has an average rating of "Hold" and a consensus price target of $188.40.

Insider Transactions at Illumina

In related news, Director Keith A. Meister sold 457,858 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,874,458 shares of company stock worth $367,996,424 in the last ninety days. 2.90% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source